前列腺MRI深度学习模型通过PI-RADS指导的学习有效区分中危病例，在检测csPCa的AUC（0.73-0.88）显著优于放射科医生和临床模型 ...

前列腺癌PI-RADS 5级病灶中11.4%活检阴性，通过多因素分析发现前列腺体积＞60cc、正常DRE、既往阴性活检、过渡区病灶及TRUS未发现可疑低回声是独立预测因素，联合应用可提升诊断准确性至AUC≥0.84，为个体化随访策略提供依据。 多参数磁共振成像（mpMRI）在前列 ...

PI-RADS version 2.1 demonstrated improved detection of clinically significant prostate cancer in the transition zone. For detecting clinically significant prostate cancer (csPCa), prostate imaging ...

Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial.

Sequential flotufolastat-F18 PSMA-PET scans to enhance detection of prostate cancer in patients with early PSA recurrence following radical prostatectomy. Prevalence of treatment-acquired homozygous ...

Upgrade and downgrade rates from targeted biopsy to radical prostatectomy were not significantly different between patients whose MRI examinations were clinically interpreted using PI-RADS Version ...

Men overestimate the risks for clinically significant prostate cancer based on prostate MRI PI-RADS findings, regardless of the context in which those risks are presented, suggesting that clinicians ...

Innovative technology performs automatic segmentation and lesion detection in prostate MRI scans to assist in PI-RADS scoring for prostate cancer management TEL AVIV, Israel & SAN JOSE, ...